Vanda Pharmaceuticals Inc (VNDA NASDAQ) stock market data APIs
$4.5038
0.11(2.4%)
as of September 12, 2025
Try our APIs with
free plan!
Vanda Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Prev. Close
4.5038
Open
4.6163
High
4.6163
Low
4.507
52 wk Range
3.8092-5.545
Market Cap
266 M
Shares Outstanding
59 089 K
Revenue
203 M
EPS
-0.46
Beta
0.739
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Vanda Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Vanda Pharmaceuticals Inc data using free add-ons & libraries
Get Vanda Pharmaceuticals Inc Fundamental Data
Vanda Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 203 M
- EBITDA: -92 869 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-31
- EPS/Forecast: -0.36
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Vanda Pharmaceuticals Inc News
New
US High Growth Tech Stocks to Watch This August 2025
As of August 2025, the U.S. stock market is experiencing a remarkable upswing, with key indices like the S&P 500 and Dow Jones Industrial Average reaching record highs amid anticipation of a significa...
Vanda asks FDA's Makary to review approval of Hetlioz generics
Noam Galai * Vanda Pharmaceuticals (NASDAQ:VNDA [https://seekingalpha.com/symbol/VNDA]) has formally asked U.S. FDA Commissioner Marty Makary to review the recently retired director of the Center f...
3 Promising Penny Stocks With Over $90M Market Cap
As the U.S. stock market experiences a downturn with the S&P 500 declining for a fourth consecutive day, investors are keenly focused on upcoming signals from Federal Reserve Chair Jerome Powell regar...
Vanda (VNDA) Q2 Revenue Rises 4%
Key Points Net loss (GAAP) widened sharply due to increased spending in Q2 2025, with GAAP EPS was ($0.46) for Q2 2025. GAAP revenue rose 4% to $52.6 million in Q2 2025 compared to Q2 2024, falling s...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
